INSIGHTS ON DRUG DEVELOPMENT
-
![Ace Patients Taste Test]( "The High Intensity Sweeteners Neotame And Sucralose")
The High Intensity Sweeteners Neotame And SucraloseLearn how high-intensity sweeteners can mask bitter aftertastes and support patient adherence, with practical guidance on stability, safety, dosage-form applications, and market perception.
-
![GettyImages-959950866-Nasal Spray Bottles]( "In Vivo Testing Of Nasal Dosage Forms")
In Vivo Testing Of Nasal Dosage FormsInnovative nasal drug delivery strategies can unlock faster, patient-friendly therapeutic solutions by combining smart formulation, advanced testing platforms, and rigorous preclinical evaluation.
-
![GettyImages-1807380795-analytics-cell-analysis-laboratory]( "Isolate Bright GFP-Expressing HEK293 Cells For Cell Line Development Workflow")
Isolate Bright GFP-Expressing HEK293 Cells For Cell Line Development WorkflowExplore a high-efficiency workflow for isolating and expanding GFP-expressing HEK293 cells that enables stable, bright clones ideal for imaging and tracking to simplify clonal development.
-
![GettyImages-1293879301-scientists-inspecting-analyzing-lab]( "Navigating Drug Design In 'Beyond The Rule Of 5' Landscape")
Navigating Drug Design In 'Beyond The Rule Of 5' LandscapeNew drug modalities are transforming treatment but bring new challenges. See how hybrid approaches that combine biologics and chemistry are redefining the design of innovative therapies.
-
Accelerate Drug Development With Phase-Appropriate Thinking9/23/2026
Successful drug development requires more than a one-size-fits-all approach. Explore strategies tailored to each stage of the journey.
-
Accelerating Development With Rapid Delivery Of Toxicological Study Material3/19/2025
Explore key strategies and technologies designed to address the analytical considerations and material flows to facilitate the rapid delivery of toxicological material.
-
From Lipids To Launch: End-To-End Therapy Development8/20/2026
Explore integrated capabilities spanning lipid manufacturing, nanoparticle formulation, and more with support designed to move complex therapies from preclinical development through commercialization.
-
Reducing Uncertainty In Early Oral Drug Development8/31/2026
Five recurring decision points in early oral solid dose development carry outsized downstream consequences. AI/ML-driven predictive modeling is reframing how teams manage those decisions under API and timeline constraints.
-
From 51% Yield To 87% With Targeted Impurity Removal5/7/2026
Targeted impurity identification and purification redesign dramatically improved yield, reduced process complexity, and enabled reliable API supply for Phase II clinical development.
DRUG DEVELOPMENT SOLUTIONS
-
![GettyImages-1218520471-development-research-lab-PPE]( "Early Development: Accelerating Molecules Through To Proof-Of-Concept")
Our integrated approach brings together drug substance, drug product and clinical activities, supporting the expediting of lead molecules from FIH into POC trials.
-
![leica-microsystems-thunder-imager-tissue-hero]( "Decode 3D Biology In Real Time - THUNDER Imager Tissue")
The THUNDER Imager Tissue allows real-time fluorescence imaging of 3D tissue sections typically used in neuroscience and histology research. Acquire rich, detailed images of thick tissues free of haze from out-of-focus blur.
Even fine structures deep in tissues can be resolved thanks to Computational Clearing, an innovative Leica technology. Image detailed morphological structures like axons and dendrites of neurons in a brain slice. The high image quality, even with thick tissue sections, is combined with the well-known speed, fluorescence efficiency, and ease of use of widefield microscopes.
-
![Fill finish vials GettyImages-1298781737]( "Lyophilization And Sterile Manufacturing")
The addition of global Sterile Fill-Finish and extensive lyophilization capabilities ensures that we are able to build on our enviable reputation and deliver on our promise of delivering life-changing therapies to patients worldwide.
-
![GettyImages-1216446418_pellets]( "Multiparticulates For Modified Release Systems")
Multiparticulates enable tailored drug release with improved flexibility, dose accuracy, and patient convenience, leveraging technologies like Diffucaps® for customized profiles including immediate, delayed, extended, and pulsatile delivery.
-
![resDNASEQ Host Cell Residual]( "Leading The Way In Rapid Quantitation Of Host Cell DNA")
Accurate, high-sensitivity quantitation of residual host cell DNA becomes faster and more consistent with integrated qPCR, automated prep, and broad assay coverage—helping streamline workflows.
